NEW DELHI - It is a low-cost Covid-19 vaccine that today holds out hope for low- and middle-income countries that have been elbowed out by richer nations amid a scramble for vaccines.
But attaining this pedestal has not been easy for the team of researchers behind this vaccine in the United States who have had to jump through several hoops to get this far.
Already a subscriber? Log in
Read the full story and more at $9.90/month
Get exclusive reports and insights with more than 500 subscriber-only articles every month
ST One Digital
$9.90/month
No contract
ST app access on 1 mobile device
Unlock these benefits
All subscriber-only content on ST app and straitstimes.com
Easy access any time via ST app on 1 mobile device
E-paper with 2-week archive so you won't miss out on content that matters to you